Clinical trials: Plasma Cell Myeloma
Multiple Myeloma, Multiple Myeloma in Relapse
Universal CAR-T Cell Therapy for MM
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT07248176
- Testing
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Bioray Laboratories
Multiple Myeloma
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide
This study will evaluate if the combination of Pomalidomide, Cyclophosphamide and Prednisone is safe and provides benefits in patients with multiple myeloma relapsed and/or refractory to lenalidomide.
- Trial name
- PCP (NCT01166113)
- Testing
- Pomalidomide, Cyclophosphamide, Prednisone
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Fondazione EMN Italy Onlus
Cancer, Lymphoma
Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies
The purpose of this study is to assess the safety and tolerability of the multi-targeted protein kinase inhibitor XL228 (active against IGF1R, Src, FGFR, and BCR-Abl) administered as a once- or twice-weekly 1-hour intravenous…
- Trial name
- NCT00526838
- Testing
- XL228
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Exelixis
Multiple Myeloma, Multiple Myeloma Progression
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and…
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
- Trial name
- NCT06644625
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 1,665 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and…
- Trial name
- NCT01056276
- Testing
- Bendamustine, Bortezomib, Dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- SCRI Development Innovations, LLC
Rheumatoid Arthritis
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
This open-label, international multi-center extension study WA18695 was designed to assess the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT00721123
- Testing
- Tocilizumab
- Where
- 69 sites in Argentina, Australia and 15 more
- Volunteers
- 538 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancy
Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies
This is a pilot sub-study of patients receiving myeloablative transplant using total body irradiation (TBI) or total marrow irradiation (TMI) in their preparative regimen.
- Trial name
- NCT02042924
- Testing
- FLT PET/CT, MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Malignancy, Blood Cancer
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular…
- Conditions
- Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia
- Trial name
- PEACE (NCT05646576)
- Testing
- Palliative Care, Usual Care
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
The main purpose of this study is to find out whether inobrodib, when given with pomalidomide and dexamethasone, works better than standard treatment for people whose multiple myeloma has come back or has not improved after…
- Trial name
- DOMMINO-2 (NCT07772024)
- Testing
- InoPd, Investigator's choice of SAT
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- CellCentric Ltd.
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study.
- Trial name
- NCT06215118
- Testing
- Elranatamab, Iberdomide
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00019097
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, melphalan
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Newly Diagnosed
A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible
This is a prospective study of anti-BCMA CAR-T in transplant-ineligible patients with newly diagnosed multiple myeloma.
- Trial name
- CAR-T (NCT07070960)
- Testing
- CAR-T
- Volunteers
- 35 people
- Sponsor
- Xuzhou Medical University
Lymphoma, Multiple Myeloma
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Primary objective 1) To assess whether oncologic and hematologic patients develop a protective immunological response after pandemic Influenza A (H1N1) vaccine Secondary objectives 1.
- Conditions
- Lymphoma, Multiple Myeloma, Myeloproliferative Disease
- Trial name
- NCT01394640
- Testing
- Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Paolo Corradini
Newly Diagnosed Multiple Myeloma
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have…
- Trial name
- NCT03733691
- Testing
- Ixazomib, Lenalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor
Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors).
- Trial name
- NCT04650724
- Testing
- T cell infusion agent targeting BCMA chimeric antigen receptor
- Where
- China
- Volunteers
- 3 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Multiple Myeloma
Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma
The purpose of this study is to evaluate the effects of daratumumab monotherapy on bone disease in patients with relapsed/refractory MM who have received at least 2 prior lines of therapy, including lenalidomide and a PI.
- Trial name
- REBUILD (NCT03475628)
- Testing
- Daratumumab
- Where
- Greece
- Volunteers
- 57 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma and Plasma Cell Neoplasm
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells.
- Trial name
- NCT00470093
- Testing
- recombinant interferon-α, recombinant interleukin-6
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma
Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are few effective treatments for MM(multiple myeloma).
- Trial name
- NCT04637269
- Testing
- anti-BCMA CAR-T
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Xinqiao Hospital of Chongqing
Multiple Myeloma
64Cu-LLP2A for Imaging Multiple Myeloma
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR).
- Trial name
- NCT03804424
- Testing
- 64Cu-LLP2A, PET/MR, Blood samples for serum stability
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine